Skip to main content
Caplight Logo









Aktis Oncology

Aktis Oncology

Public
Boston, MassachusettsBiotechhttps://www.aktisoncology.com/

Aktis Oncology is now publicly traded

The data on this page reflects Aktis Oncology's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Jan 8, 2026

Last Round

Series B

Sep 30, 2024

Total Funding Raised

$696.4M

Company Overview

Aktis Oncology is a biotechnology company that develops targeted radiopharmaceuticals for the treatment of various solid tumor cancers.

Sector

Biotech

Verticals

Life Sciences, Oncology

AI Layer

Application

Keywords

targeted radiopharmaceuticalsradiopharmaprecision oncologysolid tumor treatmentminiprotein radioconjugatescancer therapeuticsbiotech drug discoverytargeted radiation therapydrug development platformbiopharma partnershipclinical stage biotechtheranostics

Aktis Oncology Comparables

Compare Aktis Oncology with similar companies based on industry and business-model similarity.

Aktis Oncology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ratio Therapeutics Inc.
89%
Alpha-9 Oncology
86%
ARTBIO
86%

Aktis Oncology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOJan 8, 2026
Series BSep 30, 2024
Series A ExtensionAug 25, 2022
Series AMar 18, 2021

Key People

Founding team and executive leadership

Matthew Roden

President And Chief Executive Officer, And Member Of The Board Of Directors

Executive Team

Kyle Kuvalanka

Chief Financial, Chief Financial Officer

Executive Team

Shulamit Ron-Bigger

Chief Operating Officer

Executive Team

Aktis Oncology Investors

Notable investors and investment history

Aktis Oncology investors
InvestorRounds
EcoR1 CapitalSeries B, Series A, Series A Extension
Janus Henderson GroupSeries B
MPM CapitalSeries B, Series A Extension, Series A
RA Capital ManagementSeries B
TCG CrossoverSeries A, Series B, Series A Extension
A. M. Pappas & AssociatesSeries A Extension
Mirae AssetSeries A Extension

Recent news

Latest coverage and updates

  • is_developingSep 9, 2026

    Aktis Oncology, Inc. is developing novel radioconjugates.

  • has_revenueAug 13, 2026

    Aktis Oncology, Inc. had revenue of $3.38M on Aug 13th '26.

Aktis Oncology Filings

Explore SEC and related filing metadata, where available.

Aktis Oncology filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range88
Year Founded2020
Last FundingSep 30, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?